Current Melioidosis Diagnostic Landscape and Missed Opportunities in Biomarker Development

Area of Science:

• Infectious Diseases
• Biomarker Discovery
• Diagnostic Technologies

Background:

• Melioidosis, caused by Burkholderia pseudomallei, is a severe tropical disease with high mortality.
• Current diagnostic methods for melioidosis lack sensitivity, specificity, speed, or accessibility, particularly in resource-limited settings.

Purpose of the Study:

• To review current diagnostic approaches for melioidosis.
• To evaluate the potential of short peptide biomarkers for improving melioidosis detection.

Main Methods:

• A narrative literature review was performed using PubMed, Scopus, Web of Science, and Google Scholar (2000-2024).
• Studies were identified using keywords related to melioidosis diagnostics, biomarkers, and peptide-based approaches.
• Screening focused on diagnostic methods and peptide biomarker development for Burkholderia pseudomallei.

Main Results:

• Investigated biomarkers include capsular polysaccharide (CPS) and type III secretion system 1 (TTS1).
• Short peptide epitopes from these antigens offer improved stability, specificity, and lower production costs compared to whole proteins.
• Peptide-based biosensors and platforms (ELISA, LFIAs) show potential for rapid melioidosis detection.

Conclusions:

• Short peptide biomarkers are a promising strategy for developing rapid, sensitive, and cost-effective melioidosis diagnostic tools.
• These tools are particularly valuable for endemic and resource-limited settings.
• Further development of peptide-based diagnostics can significantly improve melioidosis management.